HEMOGENYX PHARMACEUTICALS PLC

AGM Information • Jun 28, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8551D

Hemogenyx Pharmaceuticals PLC

28 June 2019

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Result of Annual General Meeting

The Annual General Meeting of Hemogenyx Pharmaceuticals plc was held at the offices of Osborne Clarke LLP, One London Wall, London EC2Y 5EB on Friday 28 June 2019 at 11.00 am.

Voting on all of the resolutions was conducted on a show of hands. All resolutions were passed. The full text of each of the resolutions is set out in the notice of the meeting, which is available on the Company's website at https://www.hemogenyx.com/investors/default.aspx.

The numbers of proxy votes duly lodged prior to the meeting are set out below and will also be available on the Company's website at https://www.hemogenyx.com/investors/default.aspx.

	Proxy Votes duly lodged prior to the meeting
Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC(1)	Votes withheld
To approve the Company's annual accounts for the financial year ended 31 December 2018	119,390,068	100%	0	N/A	119,390,068	33.1%	0
To approve the directors' remuneration report contained within the annual report and accounts for the financial year ended 31 December 2018	119,386,946	100%	0	N/A	119,386,946	33.1%	3,122
To re-appoint PKF Littlejohn LLP as auditor of the Company	119,261,281	100%	0	N/A	119,261,281	33.1%	128,787
To authorise the directors to determine the level of the auditor's remuneration	119,386,946	100%	0	N/A	119,386,946	33.1%	3,122
To provide the directors with authority to allot ordinary shares	119,386,946	100%	0	N/A	119,386,946	33.1%	3,122
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC(1)	Votes withheld
To disapply statutory pre-emption rights	119,258,159	100%	0	N/A	119,258,159	33.1%	131,909

(1)           The Company's issued share capital (ISC) on 28 May 2019, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 360,176,186 ordinary shares.

(2)           A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Corporate Finance Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries	Tel: +1 (323) 646-3249
Lowell Goodman	lowell@corbomitecomms.com

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEIFFAFUSEFM